SCHEMBL1372253

SCHEMBL1372253

CC1(C)OB(c2ccc(-c3ccncc3)cc2)OC1(C)C

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 13/20 0.67
LPL P06858 12/20 0.67
F11 P03951 1/20 0.46
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
CA12 O43570 1/20 0.44
CA3 P07451 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
SNCA P37840 1/20 0.42
ESR2 Q92731 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL321437 0.88 LPL (0.53) LIPGLPLF11CA1CA2
SCHEMBL24608995 0.88 LIPG (0.83) LIPGLPLF11CA1CA2
SCHEMBL2707320 0.88 LIPG (0.83) LIPGLPLF11CA1CA2
SCHEMBL15803153 0.85 LIPG (0.49) LIPGLPLF11CA1CA2
SCHEMBL15299298 0.82 LIPG (0.59) LIPGLPLF11CA1CA2
SCHEMBL29533991 0.82 LIPG (0.69) LIPGLPLCA1CA2CA9
SCHEMBL13584589 0.82 LIPG (0.69) LIPGLPLCA1CA2CA9
SCHEMBL28389622 0.82 LIPG (0.88) LIPGLPLF11CA1CA2
SCHEMBL12681706 0.82 LIPG (0.74) LIPGLPLF11CA1CA2
SCHEMBL11996134 0.81 LIPG (0.62) LIPGLPLF11CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119080736-A Light-operated fluorescent molecular switch of targeted lysosome, synthesis and application thereof 华东理工大学 2024-12-06 CN claimed
EP-4676197-A1 MATERIAL FOR HOLE TRANSPORTATION LAYER, AND PHOTOELECTRIC CONVERSION ELEMENT AND COMPOUND USING SAME Hodogaya Chemical Co., Ltd. (JP) 2026-01-07 EP disclosed
US-20250101012-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2025-03-27 US disclosed
CN-119080736-A Light-operated fluorescent molecular switch of targeted lysosome, synthesis and application thereof 华东理工大学 2024-12-06 CN disclosed
US-12139479-B2 Heterocycle substituted pyridine derivative antifungal agents BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) 2024-11-12 US disclosed
WO-2024181493-A1 MATERIAL FOR HOLE TRANSPORTATION LAYER, AND PHOTOELECTRIC CONVERSION ELEMENT AND COMPOUND USING SAME 保土谷化学工業株式会社 2024-09-06 WO disclosed
US-11935803-B2 Resin composition, laminate, semiconductor wafer with resin composition layer, substrate for mounting semiconductor with resin composition layer and semiconductor device MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2024-03-19 US disclosed
EP-3720438-B1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS AMPLYX PHARMACEUTICALS INC (US) 2023-08-30 EP disclosed
CN-111698989-B Heterocyclic substituted pyridine derivatives as antifungal agents 安普利克斯制药公司 2023-08-01 CN disclosed
US-20230065881-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS AMPLYX PHARMACEUTICALS, INC. (US) 2023-03-02 US disclosed
EP-2468731-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT Tosoh Corporation (JP) 2012-06-27 EP disclosed
EP-2468731-A1 CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMINESCENT ELEMENT CONTAINING THESE AS COMPONENT Tosoh Corporation (JP) 2012-06-27 EP disclosed
US-20110288295-A1 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) 2011-11-24 US disclosed
US-20110288295-A1 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) 2011-11-24 US disclosed
US-20110288295-A1 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME SAGAMI CHEMICAL RESEARCH INSTITUTE (JP) 2011-11-24 US disclosed
EP-2361909-A1 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME Tosoh Corporation (JP) 2011-08-31 EP disclosed
EP-2361909-A1 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME Tosoh Corporation (JP) 2011-08-31 EP disclosed
WO-2011073845-A1 N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2011-06-23 WO disclosed
WO-2010100475-A1 HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2010-09-10 WO disclosed
WO-2010064627-A1 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME 東ソー株式会社 (JP) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101012-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS ERG28, DPM1, CYP51A1 LIPG 4496/4885LPL 4735/4885F11 4483/4885
US-20230065881-A1 HETEROCYCLE SUBSTITUTED PYRIDINE DERIVATIVE ANTIFUNGAL AGENTS ERG28, DPM1, CYP51A1 LIPG 4496/4885LPL 4735/4885F11 4483/4885
US-20110288295-A1 1,3,5-TRIAZINE DERIVATIVE, PROCESS FOR PRODUCING SAME, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME VDAC1, MT-ND5, TRPC5 LIPG 4671/4885LPL 4266/4885F11 2136/4885
US-12139479-B2 Heterocycle substituted pyridine derivative antifungal agents ERG28, DPM1, CYP51A1 LIPG 4496/4885LPL 4735/4885F11 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.